ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
A Genome-Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Article
- Genomic Analysis of Lumpy Skin Disease Virus from Western and Central Africa Suggests a Distinct Sub-Lineage Within the 1.2 LSDV Cluster.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lumpy skin disease (LSD) is an infectious cattle disease caused by the lumpy skin disease virus (LSDV), posing a serious threat to the livestock industry. This study aimed to identify specific immunogenic targets for differential diagnosis and potential vaccine development. Using a phage display library covering the entire LSDV proteome, we screened sera from naturally LSDV-infected cattle and those vaccinated with the live attenuated goatpox virus vaccine (GTPV AV41) to identify differential antibody-binding viral peptides, leading to the identification of peptides within the LSDV103 protein. A truncated recombinant LSDV103 protein (TrLSDV103) was expressed and showed strong reactivity with sera from LSDV-infected cattle, significantly higher than that with sera from GTPV-vaccinated cattle. An indirect enzyme-linked immunosorbent assay (iELISA) based on the TrLSDV103 protein was developed, with a cutoff value of 0.361, demonstrating the diagnostic specificity of 100% (95% CI: 90.11-100) and the diagnostic sensitivity of 86.67% (95% CI: 70.32-94.69). The lowest detection limit for positive serum was 1:6400, with no cross-reactivity with five other bovine pathogens. Among 210 serum samples tested, 11 were suspected of LSDV infection. Additionally, TrLSDV103 protein immunization in BALB/c mice induced strong humoral and cellular immune responses, including significantly elevated IgG levels and antibody titers up to 1:204800. Cytokine detection assays showed a significant increase in IFN-γ and IL-1β levels. Flow cytometry analysis further revealed a marked increase in CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.